Publications
- Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic2010 | Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport
- Treatment of chronic myeloid leukemia in adults in 20102010 | Faculty of Medicine in Hradec Králové
- Comments to the study Dasatinib 140 mg once daily vs dasatinib 70 mg bid in patients with CML in accelerated phase +12009 | Publication without faculty affiliation
- De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors2024 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, Faculty of Medicine in Pilsen
- Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome2021 | Second Faculty of Medicine
- Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice2021 | Publication without faculty affiliation
- First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter2019 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy2018 | First Faculty of Medicine
- The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients2018 | Faculty of Medicine in Hradec Králové
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial2018 | Publication without faculty affiliation
Loading network view...